The next ICTR Data Managers Interest Group Meeting will take place on Tuesday, November 26 at 12:30PM in the Wood Basic Science Building West Lecture Hall (Please note the location.) This meeting will feature a presentation by Tim Shields and Frank Curriero about spatial analysis and geographic information systems. Lunch will be available at noon, with the presentation and discussion beginning at 12:30PM. RSVP here: http://www.doodle.com/u4xsmzw6muw986yk
If you wish to be added to the ICTR Data Managers Interest Group listserv, click on the link below and select “Subscribe” from the menu on the left side of the page.
The Institute for Clinical and Translational Research together with The Johns Hopkins Berman Institute of Bioethics will host an ethics seminar, “HeLa Cells, the Lacks Family, and the Whole Genome Sequencing: A New Turn in the Ethics of Science?” on November 25th from 12:15-1:30pm in Feinstone Hall at the Johns Hopkins Bloomberg School of Public Health. Lunch will be provided and all are welcome to attend.
In August 2013 the family of Henrietta Lacks and the National Institutes of Health (NIH) announced a new chapter in the Lacks’ family’s interaction with science – an agreement on controlled access to genomic sequence data of HeLa cells. Berman Institute Director Ruth Faden and School of Medicine Vice Dean for Clinical Investigation Daniel Ford participated in a series of meetings and discussions with the Lacks family and NIH leadership that led to the policy. Dr. Faden now serves on the committee that reviews applications to conduct research with HeLa genome data, along with two members of the Lacks family.
In this special Berman Institute Seminar, Drs. Faden and Ford will be joined by members of the Lacks family, David Lacks and Veronica Spencer, to discuss the extraordinary process that led to this new policy, and their hopes for the legacy of Henrietta Lacks and the HeLa genome.
The National Center for Advancing Translational Sciences (NCATS) is accepting applications through January 10, 2014, for the National Institutes of Health’s Bridging Interventional Development Gaps (BrIDGs) program, part of the Common Fund.
BrIDGs, which is administered by NCATS, enables successful applicants to access critical resources needed for the development of new therapeutic agents. Those selected can work with NIH contractors, who conduct pre-clinical research at no cost to the investigator. Studies can include synthesis, formulation, pharmacokinetics and toxicology to support research-led Investigational New Drug (IND) applications to the Food and Drug Administration.
BrIDGs support is available to academic and nonprofit institutions, small businesses eligible for the Small Business Innovation Research program, and federal government agencies. Applications must be submitted online through proposalCENTRAL, and all potential applicants must participate in a pre-application teleconference with NIH program officials prior to submission. Key dates follow:
· ProposalCENTRAL Registration: November 1 through December 16, 2013
· Pre-Application Call Deadline: December 20, 2013
· Application Submission Deadline: January 10, 2014
· Expected Final Decision: September 2014
Applications are now being accepted for the Johns Hopkins Clinical Research Scholars (KL2) Program, supporting clinical research training and career development of individuals dedicated toward a career in clinical investigation. The deadline to submit applications is JANUARY 6, 2014.
There will be information sessions on Friday, November 15 from 11:30 AM to 12:30 PM and Monday, December 9 from 5:00-6:00PM in the Neil R. Powe Conference Room (1-500Q) at 2024 E. Monument Street.
To apply, please visit http://jhcrs.jhmi.edu. For more information regarding eligibility, funding and program requirements, click here or contact Gregory Thornton, JHCRS Program Manager, at email@example.com or 410-614-3997.
The Johns Hopkins Institute for Clinical and Translational Research (ICTR) will receive $72 million over the next four years to bolster its clinical research program. With this funding, the aim is to increase the number and improve the efficiency and value of clinical trials conducted at Johns Hopkins over the next few years.
To learn more; visit the links below:
News Release Courtesy of Johns Hopkins Medicine:
The Johns Hopkins University will receive $72 million over the next four years to bolster its clinical research program at its Institute for Clinical and Translational Research, or ICTR. With this funding, Johns Hopkins aims to increase the number and improve the efficiency and value of clinical trials conducted at Johns Hopkins over the next few years.
“We have a very strong clinical research program and a solid infrastructure to support translational research, and this funding allows our younger researchers to bring new ideas, new treatments and new devices into the testing phase,” says Daniel Ford, M.D., vice dean for clinical investigation at the Johns Hopkins University School of Medicine.
To help speed translational research, the Johns Hopkins ICTR provides funding for pilot studies, clinical space and staffing, biostatistics expertise and ethics and regulatory support. With this new grant, the ICTR will create three new translational research “communities.” These communities will provide researchers with the partnerships, science methodology and technical support to help faculty bring their most promising ideas related to development of drugs, biologics, diagnostic tests and behavioral interventions more quickly to market and the broader community. The grant is supported by the Clinical and Translational Science Awards (CTSA), a program led by the National Center for Advancing Translational Sciences, part of the National Institutes of Health, which supports a consortium of more than 60 research institutions across the country, all focused on strengthening translational research.
“Science and technology are progressing at an unprecedented pace, and the CTSA program — which represents NIH’s largest single investment in clinical research — is helping researchers harness these innovations and deliver improved diagnostics, treatments and cures for disease,” said NIH Director Francis S. Collins, M.D., Ph.D.
About – Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is a $6.7 billion integrated global health enterprise and one of the leading academic health care systems in the United States. JHM unites physicians and scientists of the Johns Hopkins University School of Medicine with the organizations, health professionals and facilities of The Johns Hopkins Hospital and Health System. JHM’s vision, “Together, we will deliver the promise of medicine,” is supported by its mission to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care. Diverse and inclusive, JHM educates medical students, scientists, health care professionals and the public; conducts biomedical research; and provides patient-centered medicine to prevent, diagnose and treat human illness. JHM operates six academic and community hospitals, four suburban health care and surgery centers, and 31 primary health care outpatient sites. The Johns Hopkins Hospital, opened in 1889, was ranked number one in the nation for 21 years in a row by U.S. News & World Report.
The National Center for Advancing Translational Sciences (NCATS) is a distinctly different entity in the research ecosystem. Rather than targeting a particular disease or fundamental science, NCATS focuses on what is common across diseases and the translational process. The center emphasizes innovation and deliverables, relying on the power of data and new technologies to develop, demonstrate and disseminate improvements in translational science that bring about tangible improvements in human health. For more information, visit www.ncats.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 institutes and centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical and translational medical research, and is investigating the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. View descriptions of these awardees and other CTSA institutions at www.ncats.nih.gov/ctsa-funded.html.
To learn more about how CTSA-supported investigators are translating basic discoveries into improved health, visit www.ncats.nih.gov/ctsa.html.
To learn more about the Johns Hopkins Institute for Clinical and Translational Research, visit http://ictr.johnshopkins.edu/
Up to $10,000 in funding is now available for one-year pilot grant awards to Johns Hopkins University investigators in the developmental phase of constructing novel behavioral interventions potentially impacting the lives of older adults, their families, and/or communities.
The awards, which are offered by The Center for Innovative Care in Aging at the Johns Hopkins University School of Nursing, will be granted to projects consistent with the goals and activities of the Center:
–Developing and testing of novel behavioral interventions and enhancing the yield of programs, policies, practices, and tools to help diverse older adults and family members remain healthy, independent, and living in their own homes and communities.
As the development of a behavioral intervention occurs over time and involves multiple steps and pre-testing, these small funding amounts are designed to contribute to the overall advancement of an intervention and obtaining pilot data for an NIH application (R34, R03, R21, R01 etc).
Examples of fundable projects include but are not limited to:
- Conducting semi-structured interviews or focus groups to advance intervention manual development;
- Conducting an open trial to pilot test and iteratively revise intervention protocols and a manual;
- Developing and evaluating a training program for interventionists;
- Pilot testing a new instrument for fidelity, acceptability of the intervention, or as an outcome measure;
- Translation and evaluation of a protocol, instrument or education materials for an intervention.
Funds cannot support effort of the Principal Investigator but may be used to support a research assistant, assessor, interventionist, or other research personnel, and/or honorarium for study participation.
Funding decisions will be based on scientific merit, relevance to Center goals, feasibility of completing project within one year, appropriateness of proposed project for advancing the intervention being developed, and potential for securing extramural support for the intervention concept. Funding requests of $5,000 or less will receive priority.
Who is Eligible?
Principal Investigator must hold a faculty or research appointment, or be a postdoctoral fellow at Johns Hopkins University. Pre-doctoral students are not eligible for this award.
How to Apply:
Send the following materials to firstname.lastname@example.org:
- Application proposal (2-3 pages)
- Budget and brief justification (not to exceed 1 page)
- CV or biosketch (PDF format)
Application Due: Jan. 15, 2014
Funding Decision: March 1, 2014
Start Date: April 1, 2014 (upon receipt of IRB approval)
More information: http://nursing.jhu.edu/agingpilot
The Burroughs Wellcome Fund sponsors Innovation in Regulatory Science Awards, which provides up to $500,000 over five years to academic investigators who are addressing research questions that will lead to innovation in regulatory science, with ultimate translation of those results into improving the regulatory process. These awards are intended to provide support for academic researchers developing new methodologies or innovative approaches in regulatory science that will ultimately inform the regulatory decisions the Food and Drug Administration (FDA) and others make. This would necessarily draw upon the talents of individuals trained in mathematics, computer science, applied physics, medicine, engineering, toxicology, epidemiology, biostatistics, and systems pharmacology, to name a few.
The application process consists of two phases. Applicants may submit a pre-proposal by 4:00 p.m., Eastern Time, on November 18, 2013. Forms and materials are accessible through the BWF web site. Pre-proposals selected by the Advisory Committee deemed to meet the goals of this initiative will be invited to submit full proposals that will be due April 1, 2014.
For more information, visit: http://www.bwfund.org/grant-programs/regulatory-science/innovation-regulatory-science
The next Data Managers Interest Group Meeting will take place on October 23, 12:00-1:00pm in the WBSB West Lecture Hall. The meeting will feature a presentation by Dr. Stuart Ray, Director of the Infectious Diseases Fellowship Program and Professor of Medicine in the Center for Viral Hepatitis Research in the Division of Infectious Diseases, about the secure desktop, among other topics. Lunch will be available at 11:30AM. The presentation will begin promptly at noon.
RSVP here: http://www.doodle.com/k28x66snqmn6deua
Gary Gibbons, M.D., director of the National Heart, Lung, and Blood Institute of the National Institutes of Health, delivered the keynote address at Saturday’s Fourth Annual Henrietta Lacks Memorial Lecture, sponsored by the Johns Hopkins Institute for Clinical and Translational Research.
Gibbons spoke to nearly 1,000 attendees about the importance of community involvement in scientific and medical research.
A young mother of five from eastern Baltimore County, Henrietta Lacks died in 1951 of an aggressive cancer, despite radiation treatment at The Johns Hopkins Hospital. The small tissue sample taken from Mrs. Lacks yielded cells that would help advance scientific and medical research for decades; where samples from other patients bore cells that died in days or even hours, Mrs. Lacks’ cells divided and lived on. To this day, HeLa cells — named for Henrietta Lacks — are advancing science and medicine all around the world.
As part of the pre-lecture program, Robert Blum, M.D., director of the Urban Health Institute, presented Safe Streets East with the institute’s Henrietta Lacks Memorial Award and a check for $15,000. Safe Streets East is a nonprofit organization dedicated to mediating disputes and reducing neighborhood violence in Baltimore’s McElderry Park neighborhood.
“There are few things that renew my faith in this extraordinary city more than reading the applications for the Henrietta Lacks Award,” Blum said. “This year’s winner, Safe Streets, takes a courageous public health approach to community violence and stresses intervention to interrupt the violence.”
Dunbar High School senior Rickiya Johnson received the Henrietta Lacks Memorial Scholarship, a four-year scholarship from The Johns Hopkins Hospital and school of medicine and awarded to a Paul Laurence Dunbar High School student interested in pursuing science or medicine.
“This scholarship honors Mrs. Lacks’ legacy,” said Dan Ford, M.D., M.P.H., vice dean for clinical investigation and director of the Johns Hopkins Institute for Clinical and Translational Research. “We’re proud to support a young scholar as promising as Ms. Johnson.”
Dunbar principal Kristina Kyles said Johnson “embodies Dunbar Poet Pride. She’s a three-sport athlete, a distinguished member of our school’s Emergency Medical Technology program and a certified high school first responder.” (The poet is the high school’s mascot, in honor of poet, novelist and playwright Paul Laurence Dunbar.) In addition to encouraging community participation in research and clinical trials, Gibbons saluted Mrs. Lacks.
“It’s an honor to pay tribute to a great woman,” Gibbons said in his keynote address. “I would say that Henrietta Lacks has been more prolific and has had a greater impact than any professor or scientist. She’s generated 70,000 publications in the finest journals around the world. Cell biology, cancer biology, vaccine development, drug development — it goes on and on. She has made a contribution to the commonwealth of science that is staggering.”
Keynote speakers at previous Henrietta Lacks Memorial Lectures have been author and Atlantic columnist David Ewing Duncan; Medical Apartheid author, Harriet Washington; and The Immortal Life of Henrietta Lacks author, Rebecca Skloot.
Senior Communications Specialist
Johns Hopkins Medicine
Marketing and Communications